Inhibikase Therapeutics (NYSE:IKT) Given “Neutral” Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Inhibikase Therapeutics (NYSE:IKT) in a research report sent to investors on Friday morning,Benzinga reports.

Inhibikase Therapeutics Stock Performance

Shares of NYSE:IKT opened at $2.29 on Friday. Inhibikase Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $4.20. The company’s 50-day moving average is $2.42 and its 200 day moving average is $2.40. The company has a market capitalization of $158.84 million, a P/E ratio of -0.86 and a beta of 1.04.

Institutional Investors Weigh In On Inhibikase Therapeutics

Several large investors have recently modified their holdings of IKT. Stifel Financial Corp purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at approximately $43,000. Jefferies Financial Group Inc. purchased a new stake in Inhibikase Therapeutics in the fourth quarter worth $48,000. Alpine Global Management LLC bought a new stake in shares of Inhibikase Therapeutics in the fourth quarter valued at $48,000. Caxton Corp purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at $53,000. Finally, Squarepoint Ops LLC bought a new position in shares of Inhibikase Therapeutics during the 4th quarter worth $92,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.